Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCV13 followed by PPSV23 after allogeneic hematopoietic stem cell transplant
NL-OMON36335Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Nov 2011
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of Prevnar 13 and 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease, sponsored by Pfizer. Primary endpoint: Fold rise in serotype-specific IgG geometric mean concentrations after 3 doses of PCV13. Started Nov 2011; status: active, not recruiting.
02
Drugs
Prevnar 1323-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NL-OMON36335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36335.